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Pneumococcal disease continues to account for significant morbidity and mortality worldwide. For the
development of novel prophylactic and therapeutic strategies against the disease spectrum, a complete under-
standing of pneumococcal behavior in vivo is necessary. We evaluated the expression patterns of the proven
and putative virulence factor genes adcR, cbpA, cbpD, cbpG, cpsA, nanA, pcpA, piaA, ply, psaA, pspA, and spxB
after intranasal infection of CD1 mice with serotype 2, 4, and 6A pneumococci by real-time reverse transcrip-
tion-PCR. Simultaneous gene expression patterns of selected host immunomodulatory molecules, CCL2,
CCL5, CD54, CXCL2, interleukin-6, and tomor necrosis factor alpha, were also investigated. We show that
pneumococcal virulence genes are differentially expressed in vivo, with some genes demonstrating niche- and
serotype-specific differential expression. The in vivo expression patterns could not be attributed to in vitro
differences in expression of the genes in transparent and opaque variants of the three strains. The host
molecules were significantly upregulated, especially in the lungs, blood, and brains of mice. The pneumococcal-
gene expression patterns support their ascribed roles in pathogenesis, providing insight into which protein
combinations might be more appropriate as vaccine antigens against invasive disease. This is the first
simultaneous comparison of bacterial- and host gene expression in the same animal during pathogenesis. The
strategy provides a platform for prospective evaluation of interaction kinetics between invading pneumococci
and human patients in culture-positive cases and should be feasible in other infection models.
Streptococcus pneumoniae (the pneumococcus) continues to
be responsible for significant mortality and morbidity world-
wide, causing a broad spectrum of diseases, including pneumo-
nia, meningitis, bacteremia, and otitis media (40, 64). In de-
veloping countries, up to 1 million children under 5 years of
age die each year from pneumonia, of which S. pneumoniae is
the single most common cause. Indeed, pneumonia is respon-
sible for 20 to 25% of all deaths in this age group in those
countries (77, 79). Even in developed countries, where effec-
tive antimicrobial therapy is readily accessible, morbidity and
mortality are substantial. In these countries, deaths from pneu-
mococcal disease occur primarily among the elderly, in whom
bacteremic pneumonia is associated with case-fatality rates of
10 to 20% and pneumococcal bacteremia with a case-fatality
rate of up to 60% (79). Furthermore, the less serious but highly
prevalent infections, such as otitis media and sinusitis, have a
significant impact on health care costs in developed countries.
In the United States, estimates for acute otitis media are be-
tween $1.4 billion and $4.1 billion per year. (11).
The continuing problems of pneumococcal disease are partly
attributable to the rate at which the organism is acquiring
resistance to multiple antimicrobials and the rapid global spread
of highly resistant clones (63). The problem is exacerbated by the
shortcomings associated with the current capsule-based vac-
cines, including high cost, serotype-specific protection, limited
serotype coverage, and the likelihood of replacement carriage
and disease caused by nonvaccine serotypes. Consequently,
concerted global efforts are currently focused on developing
alternative pneumococcal vaccine strategies that address these
shortcomings without compromising efficacy. One of these ap-
proaches involves the development of vaccines based on pneu-
mococcal proteins that contribute to pathogenesis and are
common to all serotypes (8, 9, 48, 51, 59).
Asymptomatic colonization of the upper respiratory tract
almost invariably precedes disease (19, 40, 64). However, the
factors and/or events that trigger the progression from naso-
pharyngeal colonization to invasive pneumococcal disease
(IPD) in certain individuals are poorly understood. This tran-
sition involves a major alteration in the microenvironment to
which the pneumococcus is exposed, which requires alteration
in the transcriptional profiles of complex sets of bacterial and
host genes. In recent years, a systematic examination of pneu-
mococcal-gene expression patterns in distinct environmental
niches has gained momentum (32, 47, 49, 54, 55). However,
progress has been hampered by technical difficulties associated
with isolating sufficient quantities of pure and intact bacterial
RNA from infected host tissues to perform accurate, quanti-
tative mRNA analyses. Furthermore, much information has
relied on discrete studies of either pneumococcal-gene expres-
sion or host innate immune responses during the pathogenesis
of disease. Consequently, there is a paucity of data on con-
comitant host innate immune responses to pneumococcal in-
fection, which could shed light directly on factors necessary for
bacterial clearance or progression to disease.
Previous mouse intranasal (i.n.) challenge experiments in
our laboratory with the virulent pneumococcal strains D39
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(serotype 2), WCH43 (serotype 4), and WCH16 (serotype 6A)
indicated that D39 and WCH43 were more virulent than
WCH16. Nevertheless, WCH16 and WCH43 had a greater
propensity to translocate to the brains of infected mice within
72 h than D39 (unpublished observations). These distinct
pathogenicity profiles are reminiscent of findings by other
workers (52) and make the three strains attractive for gene
expression analysis during disease progression. In this work, we
evaluated the gene expression patterns of proven and putative
pneumococcal virulence factors after i.n. infection of CD1
mice with the three strains. We reasoned that the relative
expression levels of genes in discrete niches should support
their ascribed roles in pathogenesis, which in turn would give
us insight into which proteins might be more appropriate as
vaccine antigens against carriage and/or IPD. Furthermore, we
hypothesized that the level of the host innate immune response
would correlate with the pneumococcal load and disease pro-
gression. The genes evaluated were those encoding choline
binding proteins (cbpA [pspC], cbpD, cbpG, pcpA, and pspA),
the pneumococcal cytotoxin pneumolysin gene (ply), the first
gene of the capsular polysaccharide biosynthesis locus (cpsA),
one of the three known pneumococcal neuraminidase genes
(nanA), ion transporter genes (psaA and piaA), a putative
Zn2-dependent regulator gene (adcR), and the pyruvate oxi-
dase gene (spxB). Each of the encoded proteins have proven or
ascribed roles in pneumococcal pathogenesis, including colo-
nization of the nasopharynx, pneumonia, sepsis, and/or men-
ingitis (1, 2, 5, 13, 14, 17, 18, 20, 22, 23, 35, 37, 38, 39, 41, 45,
47, 53, 57, 58, 64, 66, 67, 68, 69, 70, 72, 75, 80, 81). We also
investigated gene expression patterns of selected host mole-
cules known to modulate immune responses to pneumococcal
infection. They were the chemokines CCL2 (MCP-1) (78),
CCL5 (56), and CXCL2 (MIP-2) (18, 31); the inflammatory
cytokines interleukin-6 (IL-6) (3, 7, 15) and tumor necrosis
factor alpha (TNF-) (3, 28, 43, 46, 61); and intracellular
adhesion molecule 1 (ICAM-1, or CD54) (44).
We present data showing that pneumococcal virulence genes
are differentially expressed in vivo and that some genes dem-
onstrate niche- and strain-specific differential expression.
There was significant upregulation of the host molecules, es-
pecially in the lungs, blood, and brains of mice, impacting on
the ability of the host to control the infection. To our knowl-
edge, this is the first investigation in which expression levels of
pneumococcal and host response genes have been simulta-
neously compared in the same animal during progression from
nasopharyngeal colonization to invasion of the lungs, blood,
and brain.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The pneumococcal strains used in
this study were D39, a virulent type 2 strain (NCTC 7466), and virulent type 4
(WCH43) and type 6A (WCH16) clinical (blood) isolates, from the Women’s
and Children’s Hospital, North Adelaide, Australia. Serotype-specific capsule
production was confirmed by Quellung reaction, as described previously (6).
Opaque-phase variants of the three strains, selected on Todd-Hewitt broth
supplemented with 1% yeast extract (THY)-catalase plates (76), were used in all
animal experiments. Before infection, the bacteria were grown statically at 37°C
in THY broth to an optical density at 600 nm (OD600) of 0.25 (equivalent to
approximately 1  108 to 2  108 CFU/ml). The bacteria grown in this manner
also served as a source of in vitro-derived RNA.
Mice. Outbred 5- to 6-week-old female CD1 (Swiss) mice were used in all
experiments. The Ethics Committee of the University of Adelaide approved all
animal experiments.
I.n. challenge of mice for gene expression analyses. For D39 and WCH43
challenges, groups of 14 to 15 mice were used. For WCH16 challenge, two
separate challenge experiments, each comprising 12 mice, were performed. The
mice were anesthetized by intraperitoneal injection of pentobarbital sodium
(Nembutal; Rhone-Merieux) at a dose of 66 g per g of body weight and
challenged i.n. with 25 l of bacterial suspension containing approximately 1 
107 to 2  107 CFU in phosphate-buffered saline. The challenge dose was
confirmed retrospectively by serial dilution and plating of the inocula on blood
agar. At 72 h postchallenge, the mice were sacrificed by CO2 asphyxiation, and
nasal wash, nasal tissue, lung, blood, and brain samples were processed as
described previously (32, 49). A 40-l aliquot of each sample was serially
diluted in phosphate-buffered saline and plated on blood agar to enumerate
pneumococci present in each niche and to determine the presence, if any, of
contaminating microflora. Blood plates were incubated at 37°C in 95% air,
5% CO2 overnight. Samples were then stored at 80°C until further process-
ing was done. In addition, a 400-l aliquot of blood and homogenized nasal,
lung, and brain tissue was also harvested from each mouse for extraction of
eukaryotic RNA.
Extraction of total RNA from bacteria and host tissues. RNA was isolated and
purified from in vitro- and in vivo-derived bacterial pellets and host tissues with
acid-phenol–chloroform–isoamyl alcohol (125:24:1; pH 4.5; Ambion), essentially
as described previously (32). The purity of each bacterial-RNA preparation was
confirmed by one-step reverse transcription (RT)-PCR, with or without reverse
transcriptase, using 16S rRNA-specific primers, and the products were visualized
after electrophoresis on a 2% Tris-borate-EDTA–agarose gel. In all cases, a PCR
product was seen only in the presence of reverse transcriptase. The purity of
eukaryotic-RNA samples was ascertained using glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) primers in the RT-PCR in the presence of reverse
transcriptase. A single PCR product was obtained, ruling out contaminating
DNA. For bacterial RNA, samples from individual mice were selected based on
the number of CFU recovered from specific niches and also on the absence or
minimal presence of contaminating bacteria. Where indicated, bacterial-RNA
samples obtained from four or five mice from a specific niche were pooled. The
RNA was then purified further using a Qiagen RNeasy minikit. RNA obtained
from lung and brain homogenates was further enriched for prokaryotic RNA
using the MicrobEnrich kit (Ambion). The amount of RNA recovered following
purification/enrichment was determined by OD260/280 measurements.
Linear amplification of total RNA. Bacterial-RNA samples derived in vivo
(and eukaryotic RNA samples where necessary) were linearly amplified using an
advanced RNA linear-amplification kit, SenseAMP Plus (Genisphere), as de-
scribed previously (32). To obtain sufficient quantities of bacterial RNA for
real-time RT-PCR analysis, two rounds of amplification were performed for all
samples. We had previously determined that one and two rounds of RNA
amplification had high integrity and a high correlation coefficient compared to
unamplified RNA (unpublished observations).
Real-time relative qRT-PCR. The abundances of adcR, cbpA, cbpD, cbpG,
cpsA, nanA, pcpA, piaA, ply, psaA, pspA, and spxB mRNAs present in amplified
RNA recovered from pneumococci harvested from all niches were measured by
real-time relative quantitative RT-PCR (qRT-PCR). The abundances of the
selected host CCL2, CCL5, CD54, CXCL2, IL-6, and TNF- mRNA species in
the respective niches were also quantitated. Gene-specific LUX fluorogenic
primer sets labeled with JOE were designed using D-LUX primer designer
software (Invitrogen), employing primers specific for 16S rRNA (for pneumo-
coccal RNA) and GAPDH (for eukaryotic RNA) as internal controls for data
normalization (Table 1). Real-time RT-PCR was performed on a Rotorgene
RG-2000 (Corbett Research, Mortlake, NSW, Australia) using a Superscript III
One-Step RT-PCR System (Invitrogen) according to the manufacturer’s instruc-
tions. Quantitative differences for each transcript were determined using the
2CT method (34). Expression data for each bacterial gene were analyzed
relative to the level of the respective transcript in pneumococci grown in THY
broth to an OD600 of 0.25 and are presented as a relative increase/decrease
between niches.
Statistical analysis. Differences in median survival times between groups were
analyzed by the Mann-Whitney U test (two tailed). Differences in the relative
expression levels of genes between niches were analyzed by Student’s t test. All
analyses were performed using Graphpad Prism version 4.03. A P value of 0.05
was considered significant.
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RESULTS
Differences in the pathogenicity characteristics of challenge
strains. In previous mouse i.n. virulence studies using D39 (sero-
type 2), WCH43 (serotype 4), and WCH16 (serotype 6A), we
observed that D39 and WCH43 were more virulent than WCH16.
However, WCH16 and WCH43 had a greater propensity to trans-
locate to the brains of infected mice within 72 h than D39 (un-
published observations). The distinct pathogenicity characteristics
displayed by the three strains were attractive for comparative
gene expression analysis during the progression of disease from
the nasopharnyx to the lungs, blood, and brains of mice. Indeed,
bacterial counts obtained from mice infected with the three
strains 72 h postinfection showed that they colonized the naso-
pharynx at similar levels of approximately 105 CFU per mouse
(Fig. 1A, B, and C). However, WCH16 appeared to be unable to
proliferate in the lungs and blood of the infected mice to the same
TABLE 1. Oligonucleotide primers used in this study
Primera Sequence (533) Accession no.
Prokaryotic genes
16S F (JOE) CGGCCTAACTACGTGCCAGCAGC(JOE)G NC_003098
16S R GCTCGCTTTACGCCCAATAAAT
adcR F (JOE) CGGGTAACAAATTCAGAATTGGCC(JOE)G NP_346586
adcR R TTCCAACATCCCTTCCTTGACC
cbpA F (JOE) R6b CGGCGATAGTGAGGAGCGAGGC(JOE)G NP_359586
cbpA R R6b TCGCCTACGAACACTTGAAACG
cbpA F (JOE) TIGR4c CGCATTGGGAAGTGTGGTTCATG(JOE)G NP_346601
cbpA R TIGR4c TGTTCTGCCTGACTTTCATTTGC
cbpA 6B Fd TGCTAAGTTGAAGGAAGCTGTTG AAF13460
cbpA 6B R (JOE)d CGAGGTAGCTCTCCAGAAACTCCT(JOE)G
cbpD F (JOE) CGAGACAGTGGCGCATGTATTCT(JOE)G NP_346612
cbpD R TTTCCATAAGCTGCCGGAATTT
cbpG F (JOE) CGCATAGAAGGGAGGGGAAGTG(JOE)G NP_344916
cbpG R ATCCGCTTCTTTCCCATAGTCA
cpsA F (JOE) CGACACATGGTCCTATTAGTTCGGTGT(JOE)G NP_357908
cpsA R GTGGCGTTGTGGTCAAGAGG
nanA F (JOE) CGGAGAGCGCCTCAAGATATTACTC(JOE)G NP_359129
nanA R GCCCATTCCGAAGTACAATTCC
pcpA F (JOE) CGACTACGATAGCCATCGGGTGTAGT(JOE)G NP_346554
pcpA R CAATGGCTACTGGTTGGGTTACAG
piaA F (JOE) CGATTTTCAAAGTTAAGTCCATCCAAAT(JOE)G NP_358528
piaA R GCAAATTACGGTGTAAGTGCTGA
ply F (JOE) CGGACCCCCAAATAGAAATCGTC(JOE)G NP_359331
ply R TAGAGAGTGTACCGGGCTTGC
psaA F (JOE) CGTCTTATACGAACCACTTCCTGAAGA(JOE)G NP_346089
psaA R GTAAACCAAGCATTGCCACCTG
pspA F (JOE) R6b CGGCCAACAAGCTACAGACAAAGC(JOE)G NP_357715
pspA R R6b TTTGCCTCTTCTTCGCGTTTCTT
pspA F (JOE) TIGR4c CGGTGAACCTGTAGCCATAGCAC(JOE)G NP_344663
pspA R TIGR4c GGCGACAGGATGGGCTAAAG
pspA 6A Fe TTCCGTGCTCCTCTTCAATCTG AAF27701
pspA 6A R (JOE)e CGGTGTATTGTCCAGCTTGCTCAC(JOE)G
spxB F (JOE) CGGTATTTGACAGGTTCTGCTTAC(JOE)G NP_345231
spxB R GCAAATGGGAAGTTTGAACCAA
Eukaryotic genes
GAPDH F (JOE) CGGAGCAAACGGGTCATCATCTC(JOE)G NM_008084
GAPDH R CTCGTGGTTCACACCCATCAC
CCL2 F (JOE) CGGGCTTTGAATGTGAAGTTGACC(JOE)G NM_011333
CCL2 R AGTGCTTGAGGTGGTTGTGGAA
CCL5 F (JOE) CACGACGTGCTCCAATCTTGCAGTCG(JOE)G NM_013653
CCL5 R CTCTGGGTTGGCACACACTTG
CD54 F (JOE) CGGCGGGGAGGAGATACTGAGC(JOE)G NM_010493
CD54 R ACCGTGAATGTGATCTCCTTGG
CXCL2 F (JOE) CGCTGGTCTTCAGGCATTGACAG(JOE)G NM_009140
CXCL2 R CCACCAACCACCAGGCTACAG
IL-6 F (JOE) CGGACCCTTCCCTACTTCACAAGTC(JOE)G NM_031168
IL-6 R CAGGTCTGTTGGGAGTGGTATCC
TNF- F (JOE) CGAGTGGGCTACAGGCTTGTCACT(JOE)G NM_013693
TNF- R CTATGGCCCAGACCCTCACAC
a Pneumococcal- and mouse gene-specific LUX fluorogenic primer sets labeled with JOE were designed using D-LUX primer design software (Invitrogen).
b Primer sequence derived from the S. pneumoniae R6 genome as deposited in The Institute for Genomic Research (TIGR) Comprehensive Microbial Resource.
c Primer sequence derived from the S. pneumoniae TIGR4 genome as deposited in The Institute for Genomic Research (TIGR) Comprehensive Microbial Resource.
d Primer sequence derived from S. pneumoniae serotype 6B (strain BG9163) sequence as deposited in the National Center for Biotechnology Information database.
e Primer sequence derived from S. pneumoniae serotype 6A (strain DBL6A) sequence as deposited in the National Center for Biotechnology Information database.
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degree as D39 and WCH43 yet translocated to the brain as well
as WCH43 (Fig. 1C).
Gene expression profiles of opaque and transparent vari-
ants. Earlier studies had indicated that the pneumococcus un-
dergoes spontaneous phase variation between an opaque and a
transparent colony phenotype (30, 76). It was suggested that
this phenomenon might provide insight into the interaction of
the pneumococcus with its host, with the opaque phenotype
being significantly more virulent than the transparent pheno-
type (10, 76). Indeed, pilot i.n. challenge experiments in our
laboratory using opaque and transparent variants of D39 and
WCH16 indicated that the median survival times for mice
challenged with the transparent variants were significantly
longer than for mice challenged with their respective opaque
counterparts (not shown). Therefore, the in vitro expression
levels of the proven and putative pneumococcal virulence
genes adcR, cbpA, cbpD, cbpG, cpsA, nanA, pcpA, piaA, ply,
psaA, pspA, and spxB in transparent and opaque variants of the
three strains were measured by real-time qRT-PCR. We ob-
served that expression of pcpA was significantly higher in the
transparent phenotype in D39 (Fig. 2A), while the expression
levels of psaA and pcpA were significantly higher in the trans-
parent phenotype in WCH43 (Fig. 2B). Interestingly, in
WCH16, expression of cbpA was significantly higher in the
transparent phenotype, while the expression levels of nanA and
ply were significantly higher in the opaque phenotype (Fig.
2C). The expression levels of the other genes were not signif-
icantly different in the two phenotypic variants. To ensure
maximal recovery of bacteria from in vivo niches, opaque vari-
ants of all strains were used in all animal experiments.
Differential expression of virulence-associated genes. The
relative expression levels of the virulence factors in various in
vivo niches were evaluated at 72 h after challenge. This time
point was chosen because we had observed in previous mouse
i.n. challenge studies using D39 and WCH43 that the maxi-
mum recovery of virulent pneumococci was obtained from
various in vivo niches, beyond which the mice succumbed rap-
idly to infection (unpublished data). We also observed that,
72 h after challenge, bacteria plated on THY-catalase agar
were predominantly of the transparent phenotype in the nasal
wash (and in brain samples from WCH43 infection). However,
the bacteria were predominantly of the opaque phenotype in
lung and blood samples (data not shown), in agreement with
previous reports (10, 30, 51, 64, 76).
A total measure of mRNA quantities for each virulence
gene investigated in vitro and in vivo indicated that for D39
and WCH43, cpsA, ply, psaA, and pspA were the most abun-
dant while nanA, piaA, cbpD, and pcpA were the least abun-
dant (data not shown). However, for WCH16, cpsA, adcR,
psaA, and pspA were the most abundant while cbpA and nanA
were the least abundant (data not shown). A comparison of the
mRNA levels of the virulence genes in various niches relative
to levels in vitro indicated differential expression for the three
strains studied. For D39 and WCH43, data from a typical
experiment comprising pooled RNA from four or five mice are
shown in Fig. 3 and 4. Notably, sufficient RNA was obtained
from two individual mice not included in the pooled mRNA,
allowing analysis of variations in the relative in vivo expression
of the virulence genes between individual mice (see Fig. S1 and
S2 and Tables S1 and S2 in the supplemental material). How-
ever, for WCH16, insufficient RNA quantities were obtained
from the lungs and blood of individual mice due to very low
numbers of bacteria harvested from those niches (Fig. 1C).
Therefore, data from two separate experiments, comprising
FIG. 1. Bacterial recovery from various niches of CD1 mice 72 h
after i.n. challenge. The data are for D39 (A), WCH43 (B), and
WCH16 (C). For D39 and WCH43, CFU counts were from 10 mice;
for WCH16, CFU counts were for 12 mice. The horizontal lines indi-
cate the median level of CFU recovered from each niche for the
indicated strains. The limit of detection, indicated by dashed lines, was
40 CFU for nasal-wash and blood samples and 80 CFU for lung and
brain samples. ND, not detected.
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FIG. 2. Comparison of virulence gene mRNA concentrations between opaque and transparent variants of pneumococci grown in vitro.
(A) D39. (B) WCH43. (C) WCH16. Real-time RT-PCR data for each gene were normalized against those obtained for the 16S rRNA control.
The mRNA concentration was calculated as 2CT for each virulence gene, where CT represents the threshold cycle (CT) value of the gene
subtracted from the CT value of the 16S rRNA control. Values are mean 	 standard error of the mean [mRNA] opaque/transparent ratios for
each gene transcript from two replicate experiments. The data were analyzed using Student’s t test (two tailed). *, P  0.05; **, P  0.01; ***,
P  0.001.
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pooled RNA from four or five mice in each experiment, are
shown. The relative differences in virulence gene expression
between niches are presented in Tables 2, 3, and 4. It is worth
noting that, while there were some variations in the relative in
vivo expression levels of the virulence genes between individ-
ual mice, in general, the differential expression patterns of
each gene in various niches were comparable. For analytical
purposes, data for experiments involving pooled pneumococcal
RNA from four or five mice are discussed further.
Gene expression profiles show a requirement for carriage.
We observed that the mRNA expression levels of most genes
(except cbpG and spxB expression for D39 and cbpG, piaA, and
spxB expression for WCH43) were significantly higher in the
nasopharynx than those seen in vitro. Furthermore, the mRNA
expression levels of all D39 genes were significantly higher in
the nasopharynx than in the lungs and blood, except for psaA
expression in the blood, where the difference did not reach
statistical significance (Fig. 3). For WCH43, the mRNA ex-
pression levels of all genes were significantly higher in the
nasopharynx than in the lungs, blood, and brain, except for
cbpD expression in the lungs and piaA expression in the blood,
where the differences did not reach statistical significance
(Fig. 4).
In the WCH16 (serotype 6A) infection experiments, the
virulence genes were also differentially expressed in various
niches. However, the expression patterns were distinct from
those observed for D39 and WCH43. In the first of the two
WCH16 experiments, the relative expression levels of ply,
FIG. 3. D39 challenge; D39 virulence gene mRNA concentrations
in various in vivo niches relative to concentrations in vitro. Real-time
RT-PCR data for each gene were normalized against those obtained
for the 16S rRNA control. Quantitative differences for each transcript
were determined using the 2CT method (34). The data are means	
standard deviations of triplicate reactions for each gene transcript.
Data for pooled pneumococcal RNA from four or five mice are pre-
sented.
FIG. 4. WCH43 challenge; WCH43 virulence gene mRNA concentrations in various in vivo niches relative to concentrations in vitro. Real-time
RT-PCR data for each gene were normalized against those obtained for the 16S rRNA control. Quantitative differences for each transcript were
determined using the 2CT method (34). The data are means 	 standard deviations of triplicate reactions for each gene transcript. Data for
pooled pneumococcal RNA from four or five mice are presented.
TABLE 2. Differential expression of D39 virulence genes
in various niches
Gene
Expressiona
Nose vs. lungs Nose vs. blood Lungs vs. blood
adcR 11.5d 10.6d 1.1
cbpA 21.1d 5.9c 3.6c
cbpD 4.1d 2.9b 1.4
cbpG 5.9c 2.4b 2.5c
cpsA 5.1d 4.6c 1.1
nanA 3.9d 9.1d 2.4c
pcpA 21.4d 5.7c 3.8c
piaA 21.3d 15.5d 1.4
ply 9.3d 2.5b 3.7c
psaA 3.9c 2.4 1.7b
pspA 50.9d 30.1d 1.7c
spxB 237.2d 172.5d 1.4
a The values represent the relative amounts of mRNA in the first niche com-
pared to the second. Data were analyzed using Student’s t test (two-tailed).
b P  0.05.
c P  0.01.
d P  0.005.
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pspA, and spxB were significantly higher in the nasopharynx
than in other niches, but the expression levels of cbpA, cbpG,
cpsA, and pcpA were significantly higher only in the nasophar-
ynx than in the blood. Indeed, expression levels of cbpA and
cpsA were significantly higher in the lungs than in the naso-
pharynx, while the expression levels of adcR, cbpG, and pcpA
were significantly higher in the lungs and brain than in the
nasopharynx (Fig. 5A). However, gene expression patterns in
the second WCH16 experiment were largely dissimilar to those
of the first experiment (Fig. 5B). These discrepancies could be
attributed to generally low numbers of bacteria harvested from
the lungs and blood of mice infected with WCH16 (Fig. 1C).
Nevertheless, in general terms, data from the two WCH16
experiments indicate consistent trends in gene expression for
cbpA, cbpG, cpsA, pcpA, piaA, ply, pspA, and spxB (Fig. 5).
Strain- and niche-specific differential expression of viru-
lence factors. We observed that there was a high level of
similarity in the patterns of in vivo expression of the majority of
the virulence factors for D39 and WCH43. However, certain
genes demonstrated strain- and niche-specific differential ex-
pression. For instance, while the relative expression levels of
cbpA were higher in WCH43 and WCH16 harvested from all in
vivo niches than that obtained in vitro (Fig. 4 and 5A), its
relative expression levels were lower in the lungs and blood of
mice challenged with D39 (Fig. 3). However, pspA expression
was lower in the lungs and blood of mice challenged with
WCH43. In addition, the expression levels of nanA were higher
in the nasopharynx and lungs than in vitro for D39 and in all
the in vivo niches for WCH43, but its expression levels were
quite similar in vitro and in vivo for WCH16. Furthermore, in
the brain, the relative mRNA concentration of spxB was low
for WCH43 but was very high in the same niche for WCH16.
Finally, it was interesting that cbpG expression was downregu-
lated in all in vivo niches for D39 and WCH43 but upregulated
in all in vivo niches for WCH16.
Host innate immune responses correlate with infection in
discrete niches. The mRNA levels for genes encoding host
factors known to modulate immune responses to pneumococ-
cal infection were measured 72 h after challenge with the three
strains. In the nasal tissue, mRNA expression levels of CCL2,
CD54, and CXCL2 were significantly higher in D39-infected
mice than in naı¨ve mice (Fig. 6A). A similar result was ob-
tained with WCH43-infected mice, but in addition, the mRNA
expression level of CCL5 was also significantly higher in in-
fected nasal tissue (Fig. 6A). However, in the nasal tissues of
WCH16-infected mice, there was massive upregulation of the
mRNAs of all host genes studied (Fig. 6A).
In the lungs, the mRNA levels of all host genes studied were
significantly higher in D39-infected mice than in the lungs of
naı¨ve mice (Fig. 6B). Again, a similar result was obtained in
WCH43-infected mice. However, expression of CCL5 and
CD54 was not upregulated in the lungs of WCH43-infected
mice (Fig. 6B). Interestingly, while there was significant up-
regulation of CCL2, CCL5, CXCL2, IL-6, and TNF- mRNAs
in the lungs of WCH16-infected mice, CD54 mRNA expres-
TABLE 3. Differential expression of WCH43 virulence genes
in various niches
Gene
Expressiona
Nose vs.
lungs
Nose vs.
blood
Nose vs.
brain
Lungs vs.
blood
Lungs vs.
brain
Blood vs.
brain
adcR 6.8d 21.7d 7.6c 3.2d 1.1 2.9b
cbpA 4.1d 7.3d 5.6d 1.8c 1.4 1.3
cbpD 2.5c 11.9d 1.4 4.9c 3.4c 16.3d
cbpG 3.9d 31.1d 2.1b 7.9d 1.9 14.9d
cpsA 3.9d 9.8d 3.4d 2.5c 1.2 2.9c
nanA 6.1d 15.9d 4.2c 2.6d 1.5 3.8d
pcpA 6.2d 17.4d 13.6d 2.8d 2.2b 1.3
piaA 3.7c 5.2d 3.0b 1.4b 1.3 1.7b
ply 16.1d 294.1d 10.3d 18.2d 1.6 28.3d
psaA 2.6c 3.7d 11.2d 1.4b 4.3d 3.1c
pspA 22.0d 69.6d 22.6d 3.2c 1.0 3.1c
spxB 14.0d 34.3d 7.9d 2.5c 1.8b 4.4d
a The values represent the relative amounts of mRNA in the first niche com-
pared to the second. Data were analyzed using Student’s t test (two-tailed).
b P  0.05.
c P  0.01.
d P  0.005.
TABLE 4. Differential expression of WCH16 virulence genes in various niches
Gene
Expressiona
Nose vs. lungs Nose vs. blood Nose vs. brain Lungs vs. blood Lungs vs. brain Blood vs. brain
Expt 1 Expt 2 Expt 1 Expt 2 Expt 1 Expt 2 Expt 1 Expt 2 Expt 1 Expt 2 Expt 1 Expt 2
adcR 10.2d 2.2c 1.7d 23.1d 15.1d 17.0d 6.0d 45.2d 0.7d 8.7d 8.8d 392.5d
cbpA 2.0b 1.7 27.7c 4888.2d 1.0 563.5d 56.8c 4943.2d 2.1b 327.4d 27.8d 5019.3c
cbpD 5.6d 3.8d 1.1d 14.6d 23.4d 3.1c 4.9d 55.8d 4.2d 1.2 20.8c 45.5d
cbpG 5.0d 3.3c 6.0d 551.3d 20.0d 260.2d 29.8d 167.7d 4.0d 79.2d 119.4c 2.1c
cpsA 2.0c 2.0 69.7c 2.1c 1.7b 4.17c 142.7d 1.0 3.6d 210b 40.0d 2.0b
nanA 1.9 1.0 2.0 1.1d 10.1d 1.0d 1.0 1.1d 12.2d 1.0d 12.2c 2.1d
pcpA 9.4d 2.6d 3.8d 1323.4d 27.9d 57.6d 36.0d 3444.3d 3.0d 149.8d 107.1c 23.0d
piaA 3.0c 3.5b 1.10 16.3c 1.0 1.30 3.5c 4.7c 3.0c 4.76c 1.1 22.2c
ply 2.7b 1.8 3.7c 2.0 2.2c 1.0 1.4b 1.0 1.2 1.9b 1.7b 2.0b
psaA 1.5 3.0b 1.79 3.7c 2.0c 705.2c 1.2 1.2 3.2c 1.9b 3.6b 2598d
pspA 2.6c 1.9b 1.8b 1.1 6.0c 3.23b 1.5b 1.7b 2.3c 1.7 3.3d 2.9b
spxB 8.5c 8.2b 25.7d 37.5b 1.2 222.2b 3.0 4.6b 7.1d 1428.6b 22.2d 6666.7b
a The values represent the relative amounts of mRNA in the first niche compared to the second. Data were analyzed using Student’s t test (two-tailed).
b P  0.05.
c P  0.01.
d P  0.005.
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sion was significantly downregulated compared to levels in the
lungs of naı¨ve mice (Fig. 6B). In the blood, the mRNA expres-
sion levels of all host genes studied were significantly higher in
D39- and WCH43-infected mice than in naı¨ve mice. However,
in WCH16-infected mice, the level of CD54 expression was
similar to that seen in naı¨ve mice (Fig. 6C). Finally, there was
significant upregulation of all host mRNA genes studied in the
brain tissues of WCH43- and WCH16-infected mice (Fig. 6D).
DISCUSSION
The pathogenesis of pneumococcal disease is a complex
process involving a series of interactions between pathogen
and host. During disease progression, the pneumococcus must
adapt to a range of environments, such as the nasopharyngeal
and lung mucosa, blood, and cerebrospinal fluid, and optimal
survival in distinct host niches requires differential expression
of virulence factors. Several well-characterized pneumococcal
virulence factors are known to contribute to pathogenesis (1, 2,
5, 13, 14, 17, 18, 20, 22, 23, 35, 37, 38, 39, 41, 45, 47, 53, 57, 58,
64, 66, 67, 68, 69, 70, 72, 75, 80, 81). In recent years, direct
molecular evidence for pneumococcal-gene expression pat-
terns in the distinct environmental niches has emerged (32, 47,
49, 54, 55), but it is limited to discrete examination of either
pneumococcal-gene expression or host innate immune re-
sponses. In this work, we investigated virulence gene expres-
sion in three pneumococcal strains and simultaneous host
cytokine responses in a murine model. Our objective was to
gain new insight into pneumococcal behavior in vivo and to
dissect bacterial and host factors necessary for clearance or
progression to disease.
We observed that the pneumococcal virulence genes exam-
ined are differentially expressed in various in vivo niches. This
is not altogether surprising and presumably reflects the relative
contributions of these factors at different stages of the patho-
genic process. The niche-specific differences were not attribut-
able to phase variation, which had only minor effects on the
relative [mRNA] for these genes between transparent and
opaque phenotypes. The expression levels of the vast majority
of the genes were relatively high in the nasopharynx for the
three strains, implying a requirement for carriage. This study
thus provides direct molecular evidence supporting the hy-
FIG. 5. WCH16 virulence gene mRNA concentrations in various in vivo niches relative to concentrations in vitro. Real-time RT-PCR data for
each gene were normalized against those obtained for the 16S rRNA control. Quantitative differences for each transcript were determined using
the 2CT method (34). The data are means 	 standard deviations of triplicate reactions for each gene transcript. Data for pooled pneumococcal
RNA from four or five mice from two independent experiments (A and B) are presented.
VOL. 76, 2008 PNEUMOCOCCAL AND HOST GENE EXPRESSION IN VIVO 653
pothesis advanced by others (10, 22, 23, 53) that many pneu-
mococcal virulence factors have dual roles in the establishment
and maintenance of carriage, as well as involvement in certain
stages of invasive disease.
It is striking that while in vivo expression patterns for the
majority of the genes were similar across the three strains,
some genes demonstrated strain- and niche-specific differential
expression. For example, the relative expression levels of cbpA
were higher in WCH43 and WCH16 harvested from all in vivo
niches than that obtained in vitro but lower in the lungs and
blood of mice challenged with D39. This finding provides mo-
lecular evidence that explains the discordance in the literature
regarding the effects of cbpA mutation on the virulence of
different pneumococcal strains (6, 29, 51, 53). However, up-
regulation of cbpA expression in the brains of WCH16- and
WCH43-infected mice is consistent with its putative role in
adherence to, and invasion of, the brain microvascular endo-
thelium (53, 60, 64, 81). Interestingly, pspA expression was
opposite to that obtained for cbpA expression, being upregu-
lated in the lungs and blood of D39-infected mice but down-
regulated in the same niches for WCH43-infected mice. This
agrees with the suggestion that the virulence properties of
CbpA and PspA may complement each other in the host (12).
Upregulation of pspA expression in the lungs and blood of
D39-infected mice correlates with attenuation of an isogenic
pspA mutant in pneumonia and bacteremic infection models
(6, 51). Downregulation of pspA in WCH43 recovered from the
lungs and blood could indicate that PspA does not contribute
as significantly to pneumonia and sepsis in this serotype and
might explain why PspA immunization does not offer effective
protection against serotype 4 strains in mice (24, 65).
The differential expression of nanA in D39 and WCH43 in
vivo, but not in WCH16, implies a role for NanA in pathogen-
esis in various serotypes and suggests that its expression is
probably not essential for virulence in WCH16. Furthermore,
spxB was highly upregulated in the brain for WCH16 but down-
regulated in the same niche for WCH43. Downregulation of
spxB in the brain has also been demonstrated in another sero-
type 4 strain, albeit in a rabbit model (54). Expression levels of
genes, such as adcR, cbpD, cpsA, pcpA, and psaA, were consis-
tently high in various in vivo niches, implying pleiotropic effects
on pathogenesis. Indeed, this has been demonstrated for the
capsule (1, 2, 35, 41, 45) and PsaA (5, 19, 39). Expression of
piaA was generally downregulated in the lungs, blood, and
brain, implying functional redundancy with similar iron acqui-
sition proteins. Upregulation of cbpG expression in all in vivo
niches only for WCH16 suggests that CbpG could be important
for pathogenesis in this strain, where it may have a dual role on
mucosal surfaces and in the blood (17).
Based on the comprehensive assessment of in vivo gene
expression patterns for the three strains, such information
could be used in lieu of mutagenesis studies to assess niche-
specific roles of novel virulence genes during pathogenesis,
particularly for strains that are difficult to transform. In such
instances, including an invariantly expressed gene (such as
cpsA or psaA) would validate the fidelity of the assay. For
FIG. 6. Host mRNA responses to S. pneumoniae D39, WCH43, and WCH16 at 72 h postinfection. Relative mRNA concentrations for each
gene in the nasopharynges (A), lungs (B), blood (C), and brains (D) of mice are shown. Real-time RT-PCR data for each gene were normalized
against those obtained for the GAPDH mRNA control. The data are means 	 standard deviations of triplicate reactions for each gene transcript.
Data for pooled RNA from four or five mice are presented. *, P  0.05; **, P  0.01; ***, P  0.001.
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pneumococcal protein vaccine development, the strain- and
niche-specific expression data provide an additional rationale
for multiple protein combinations to obtain broader coverage.
This proposition is exemplified by cbpA, pspA, ply, and psaA
expression profiles, which parallel their documented roles and
protective efficacies in colonization and invasive disease, either
alone or in combination (8, 9, 12, 48, 50, 59).
With regard to the host innate immune response, all the
tested host molecules were significantly upregulated, especially
in the lungs, blood, and brain tissues of mice infected by the
three strains. The response most likely corresponds to the
intense inflammation usually observed during severe pneumo-
coccal pneumonia in humans, which often leads to tissue in-
jury, shock, and death (4, 15, 16, 26, 71, 73). The expression of
TNF- is important for surviving pneumococcal infection but
may also cause inflammatory host injury under certain condi-
tions (61). TNF- is capable of recruiting inflammatory cells to
the site of infection, directly and via upregulation of adhesion
molecules (46) and by stimulating the release of cytokines that
are directly chemotactic for inflammatory cells (28). IL-6 can
activate monocytes (7) and can synergize with TNF- to in-
crease the respiratory burst of neutrophils (43). Another study
highlighted the involvement of high levels of IL-6 in the lethal-
ity of pneumococcal infection (15). Upregulation of TNF-
and IL-6 in the blood of D39- and WCH43-infected mice may
be partly due to upregulation of Ply in the blood, as reported
previously (3). Indeed, Ply has been shown to activate murine
macrophages (27), resulting in the secretion of TNF- and
IL-6, proposed to occur through Toll-like receptor 4 signaling
(36). Ply also stimulates expression of TNF- and IL-1 from
monocytes (25), as well as that of CD54, an important com-
ponent of the leukocyte-trafficking system (71). Surprisingly,
CD54 expression was significantly downregulated in the lungs
of WCH16-infected mice and was not significantly upregulated
in the blood. While the reason for this observation is not
immediately clear, we speculate that it could be due, in part, to
lower expression of ply in the lungs and blood of WCH16-
infected mice.
Transcription of pspA increased in the nasopharynges of
infected mice, consistent with the role of PspA in protecting
pneumococci from being killed by apolactoferrin at mucosal
sites (69). In contrast, pspA expression in D39 was lower in the
lungs than in the nasopharynx or blood. The absence of PspA
was previously suggested to limit the chemokine response in
the lungs, and deletion of pspA had minimal impact on the
chemokine responses of Detroit-562 cells to S. pneumoniae
(18). This suggests that PspA may not play a significant role in
generating a CXC chemokine response from nasopharyngeal
epithelial cells. However, in the current study, CCL2, CCL5,
and CXCL2 chemokines were highly expressed in the lungs of
mice infected with D39, implying that other factors could be
responsible for these responses.
Our results also showed that the chemokine response was
higher in the lungs and blood than in nasal tissue. It was
previously shown that CbpA may suppress CXC chemokine
production by nasopharyngeal epithelial cells, thereby promot-
ing colonization by preventing the neutrophil recruitment re-
quired for bacterial clearance (18). CbpA has also been shown
to elicit cytokine and ICAM-1 expression from human alveolar
epithelial cells (44). In the lungs, an early, sharp host innate
immune response was shown to be vital in overcoming pneu-
mococcal infection (15). Thus, CbpA-mediated attenuation of
this response may prevent clearance, leading to a sustained
inflammation that aids pneumococcal entry into the blood.
While PspA and CbpA have significant and differential effects
on chemokine responses of respiratory epithelial cells in vitro,
effects on other cell types could influence the overall host
response in a given niche. Moreover, other proinflammatory
factors, such as lipoteichoic acid and Ply, are likely to contrib-
ute. Indeed, it was shown that Ply, PspA, and CbpA (PspC) all
contribute to pneumococcal evasion of early innate immune
responses during bacteremia in mice (62, 80). The involvement
of proinflammatory cytokines, CXC chemokines, and cell
adhesion molecules in pneumococcal meningitis is well estab-
lished (31, 60, 74, 82). Thus, it is not surprising that these
molecules were significantly upregulated in the brain tissues of
WCH43- and WCH16-infected mice, likely in response to cbpA
expression (53, 60, 64, 81).
For WCH16-infected mice, a significant finding was that the
tested host molecules were massively upregulated in the naso-
pharynx and brain. This could explain why WCH16 is not as
virulent as D39 and WCH43. Indeed, none of the WCH16-
infected mice died before the 72-h end point of the experi-
ments. These results correlate with that reported in another
study (33) using different challenge and mouse strains, that
distinct cytokine profiles characterize pneumococcal carriage,
self-resolving pneumonia, and lethal disease. In that work, the
authors proposed that activation of the immune system re-
sulted in nonlethal disease for a serotype 6B strain (as seen for
WCH16), whereas evasion of the immune system resulted in
detrimental disease for serotypes 3 and 14, as observed for D39
and WCH43.
The results of this work open new vistas in the study of
pneumococcal gene expression and host response during
pathogenesis of invasive disease. Future studies examining
global pneumococcal and host gene transcriptional profiles,
and at earlier time points (e.g., 24 h and 48 h), will provide a
more comprehensive analysis of pneumococcal and host gene
expression kinetics. It will also be important to correlate
mRNA transcript levels in bacteria and host tissues with pro-
tein levels in such experiments. Such studies will also neces-
sarily include a dissection of the bacterial transcription factors
that regulate gene expression in response to different host
environmental cues and the host signals that trigger the expres-
sion of those factors. Analysis of the key events that control these
interactions will increase our understanding of pneumococcal
pathogenesis, as well as aid in the design of appropriate tools to
control the inflammatory response.
In conclusion, the relative expression levels of pneumococcal
virulence genes in discrete niches support their ascribed roles
in pathogenesis and provide insight into which proteins and
combinations thereof might be more appropriate as vaccine
antigens against carriage or IPD. There was significant host
innate immune response, impacting on the ability of the host to
control the infection. One previous study employed microarray
technology for simultaneous analysis of host-pathogen interac-
tions in a localized murine granulomatous pouch infection
model using a virulent Escherichia coli strain (42). Other stud-
ies have used in vivo expression technology, signature-tagged
mutagenesis, differential fluorescence induction, and subtrac-
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tive hybridization to measure bacterial-gene expression in vivo
(reviewed in reference 21). Our approach is unique, providing
a platform to directly examine the kinetics of pneumococcal-
and host gene expression from asymptomatic colonization to
the establishment of invasive disease. To our knowledge, this is
the first comprehensive investigation in which the expression
levels of bacterial and host response genes have been simulta-
neously compared in the same animal during pathogenesis
using a model that mimics human disease. The strategy could
be directly applied to prospective evaluation of the interactions
between invading pneumococci and human patients in culture-
positive cases and should be broadly applicable to the analysis
of in vivo molecular interactions between other bacterial
pathogens and their respective hosts in appropriate infection
models. Such studies would be pertinent to the development of
improved prophylactic and therapeutic interventions.
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